Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenomic Evaluation of Antihypertensive Responses 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* An average seated home diastolic blood pressure (DBP) \> 85 mmHg and \< 110 mmHg and home systolic blood pressure (SBP) \< 180 mmHg.~* Subjects must also have an average seated (\> 5 minutes) clinic DBP between 90 mmHg and 110 mmHg and SBP \< 180 mmHg~Exclusion Criteria:~* Secondary forms of hypertension (HTN) (including sleep apnea)~* Isolated systolic HTN~* Other diseases requiring treatment with BP lowering medications~* Heart rate \< 55 beats/min (for metoprolol only)~* Known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease, including stroke and TIA)~* Diabetes mellitus (Type 1 or 2)~* Renal insufficiency (serum creatinine \> 1.5 in men or 1.4 in women)~* Primary renal disease~* Pregnancy or lactation~* Liver enzymes \> 2.5 upper limits of normal~* Current treatment with NSAIDS, cyclooxygenase-2 (COX2) inhibitors, oral contraceptives or estrogen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Metoprolol + Chlorthalidone (Type: EXPERIMENTAL): Study participants in this group had their current hypertension treatment withdrawn, baseline labs drawn and hypertension documented. Participants were initiated on metoprolol tartrate 50 mg twice daily for two weeks, followed by dose titration to 100 mg twice daily for six additional weeks if blood pressure (BP) \> 120/70 mmHg. BP measures were again recorded. Participants entered a washout where metoprolol was titrated, then discontinued, and the patient's hypertension was re-established. After another set of identical baseline labs, study participants were initiated on chlorthalidone 25 mg four days per week (Monday, Wednesday, Thursday, Saturday) 15 mg daily for two weeks, followed by 25 mg daily for an additional six weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).